S
elective killing of cancer cells using suicide systems like the herpes simplex-thymidine kinase/ganciclovir system or the bacterial cytosine deaminase (CD)/5-fluorocytosine (5FC) system is an attractive strategy for cancer gene therapy. [1] [2] [3] [4] CD, which is not expressed in mammalian cells, converts the nontoxic prodrug 5FC into the highly toxic substance 5-fluorouracil (5FU). 5, 6 Therefore, cells genetically modified to express the CD suicide gene can selectively produce 5FU and its metabolites, which upon inhibition of DNA replication and incorporation into RNA finally cause cell death. 7 In addition to this suicidal effect on gene-modified cells, toxicity is also exerted on adjacent, CD-negative cells. This so-called "bystander" effect has been described in vitro and in vivo. 2,8 -10 In contrast to the thymidine kinase suicide system, whose toxic metabolite is phosphorylated (ganciclovir-monophosphate) and whose bystander effect was shown to depend upon gap junctions, 11 the toxic metabolite of the CD suicide system, 5FU, can diffuse through the cell membrane, thereby causing cellular toxicity to neighboring cells. 9, 12 For gene therapy approaches, the bystander effect is important, because not all tumor cells can be reached by current gene transfer systems. In vivo experiments have shown that only a small percentage of CD-expressing cells can cause short-term tumor regression, but recurrence of tumors was observed subsequently. 9, 13, 14 Diffusion of 5FU itself cannot account for the ablation of a tumor mass consisting predominantly of unmodified cells. Several studies have suggested that part of the bystander effect in vivo can be assigned to the development of an antitumoral immunity that might contribute to tumor regression. [15] [16] [17] [18] In thymidine kinase-expressing tumors, infiltrates of mononuclear cells, such as macrophages and T lymphocytes, were observed. 16, 19 Similarly, CD4 ϩ and CD8 ϩ lymphocytes are required for rejection of CD-expressing tumors and protection against further tumor challenges. 17, 20 Moreover, the antitumoral reaction could be enhanced by combining the suicide gene with the expression of cytokine genes. [21] [22] [23] [24] In the present study, we established a strategy for inducing antitumoral immunity. Using the rat pancreatic carcinoma cell line AS, we were able to show that this syngeneic, poorly immunogenic tumor can be eliminated upon expression of CD in the absence of the prodrug. This vaccination strategy protected AS/CD-vaccinated animals against subsequent challenges with CD-modified as well as parental tumor cells. Moreover, we were able to confirm an immune response by detection of tumor cell-specific cytotoxic T lymphocytes (CTLs) in these animals.
MATERIALS AND METHODS

Cell lines
The parental tumor cell line AS (BSp73AS) was originally derived from a spontaneous pancreatic adenocarcinoma of a 26-monthold BDX rat. 25 The AS cells are poorly immunogenic, nonmetastatic, and exhibit highly aggressive tumor growth in BDX rats. Sp6S is a syngeneic sarcoma cell line of BDX rats. The YAC cell line is derived from a mouse lymphoma that does not express major histocompatibility complex (MHC) class I molecules and is known for its sensitivity to natural killer (NK) cells. All cells were grown in RPMI 1640 medium (Life Technologies, Eggenstein, Germany) supplemented with 10% heat-inactivated fetal calf sera (Life Technologies), 100 U/mL penicillin, 100 g/mL streptomycin (Life Technologies), and 4 mM L-glutamine (Life Technologies).
Vectors and gene transfer
The construction of the eukaryotic expression plasmid pUHD10-1/CD (CMV-CD), coding for CD, as well as all transfection procedures were performed as described previously. 26 Briefly, AS/CD and AS/neo cells were obtained by cotransfection of plasmid pSV2neo 27 with pUHD10-1/CD or pUHD10-1. Selection was performed with 0.8 mg/mL G418 (Life Technologies). CD-expressing clones were identified by flow cytometry (with a fluorescence-activated cell sorter (FACS)) using the anti-CD monoclonal antibody (mAb) 16D8F2. 26 Subcloning of CD transfectants was performed by limiting dilution, and the resulting clones were examined again for CD expression using a FACS. One AS/CD clone with high CD expression and one AS/neo clone were chosen for subsequent in vitro and in vivo experiments.
In vitro drug-sensitivity assay AS/neo or AS/CD cells (5 ϫ 10 2 ) were plated on 96-well plates in triplicate and exposed 24 hours later to different concentrations (0 -50 mM) of 5FC or 5FU (Sigma, München, Germany). Treatment with 5FC or 5FU was continued for 6 days with daily medium changes. The relative number of viable cells was determined using the 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) (Sigma) assay. 28 Color precipitates were measured in an enzyme-linked immunosorbent assay microplate reader (EAR340AT; SLT Lab Instruments, Grödig, Austria) at 560 nm with a reference filter of 620 nm. 
Animal experiments
For the in vivo experiments, 10-to 12-week-old female BDX rats (WIGA, Sulzfeld, Germany) were used. Two independent experiments were performed, with three animals per group in the first experiment and five animals per group in the second experiment. A total of 5 ϫ 10 6 tumor cells were resuspended in 200 L of phosphate-buffered saline (PBS) and inoculated subcutaneously (s.c.). This tumor cell dose is about two orders of magnitude above the number of cells required to generate AS tumors in 50% of these animals. 25 Tumor size (cm 2 ) was determined by measuring the largest and smallest diameter as tumor length (cm) ϫ tumor width (cm). If tumor size reached 3 cm in diameter, animals were euthanized. At 11 days after the first inoculation of AS/CD or AS/neo tumor cells, 500 mg of 5FC/kg body weight (stock concentration of 50 mg of 5FC/mL PBS) was administered intraperitoneally (i.p.) once daily for 2 weeks followed by administration once in 2-day intervals in the third week. Control animals received PBS (i.p.) only. At 50 days after the first tumor cell challenge, surviving animals were inoculated again with tumor cells. The second tumor cell challenge was performed three weeks after the complete AS/CD tumor regression. The rats received inoculations of 5 ϫ 10 6 AS/CD cells into the left flank and 5 ϫ 10 6 AS cells into the right flank. Animals that survived the second tumor cell challenge were inoculated for the third time with 5 ϫ 10 6 AS cells into the left flank. The third challenge, 106 days after the first tumor challenge, was performed 4 weeks after the complete regression of the AS tumors. After the second and third challenges, no 5FC treatment was performed. For each of the three experimental steps, untreated naive animals were used as controls to determine the tumorigenicity of AS cells. Tumor growth was examined two to seven times weekly as described above. Animals were monitored until they had to be sacrificed due to tumor size or until preparation of lymphocytes from surviving rats at the end of the experiment.
For the preparation of peripheral blood lymphocytes (PBLs) for chromium release assay, heparinized blood was drawn or the spleens were taken from sacrificed animals and lymphocytes were purified using a Ficoll gradient. Cells were stored in liquid nitrogen in 10% dimethylsulfoxide (Merck, Darmstadt, Germany)/fetal calf serum.
Immunohistochemistry
Tissues were snap-frozen in liquid nitrogen and stored at Ϫ80°C. Acetone-fixed 6-m cryostat sections were washed in PBS, treated with 3% hydrogen peroxide for 5 minutes, and washed again with PBS. Blocking was performed with rabbit sera (Dako, Hamburg, Germany; 1/5 dilution in PBS) for 20 minutes at 37°C. After washing with PBS, tissue sections were overlaid with biotinylated anti-rat CD4 (0.5 g/mL OX 38; PharMingen, Hamburg, Germany; 1/10 dilution) or anti-rat CD8 (0.5 g/mL OX 8; PharMingen; 1/10 dilution) antibodies (Abs) for 2.5 hours at 37°C. After PBS washing, streptavidinconjugated horseradish peroxidase (Dako) was incubated for 10 minutes at room temperature. For signal detection, sections were rinsed with PBS and subsequently incubated with highsensitivity substrate-chromogen 3-amino-9-ethylcarbazole (Dako) for 30 -40 minutes. Counterstaining was performed with hematoxylin.
Chromium release assay
PBLs were cultured in cell culture medium (see above) supplemented with 2 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid (pH 7.3) (Roth, Karlsruhe, Germany), 2 ϫ 10 Ϫ5 M ␤-mercaptoethanol (Merck), and T-cell growth factor (cell culture supernatant of mitogen-treated rat spleen cells, 1:10). Cr-labeled (sodium 51-chromate; 100 Ci for 60 minutes) AS, AS/CD, Sp6S, or YAC target cells at different effector to target cell (E:T) ratios (40ϫ, 13.3ϫ, 4.4ϫ, 1.5ϫ). Supernatants were measured in a ␥ counter (1282 Compugamma; LKB-Wallac, Stockholm, Sweden) and the percentage of specific lysis was calculated according to the following equation: Specific lysis ϭ ([experimental cpm Ϫ spontaneous cpm]/ [maximum cpm Ϫ spontaneous cpm]) ϫ 100%. Each experiment was performed in triplicate.
Statistics
All results were obtained from two independent experiments with three and five rats per group, respectively, and data were accumulated. The significance of differences in tumor size was determined by a "two-sided" Wilcoxon rank-sum test. The statistical analysis of the survival rates was performed by a log-rank test. P values of Ͻ.05, after correction according to Bonferroni-Holm, were considered significant.
RESULTS
In vitro characterization of the AS/CD tumor cell line
A stably transfected AS/CD clone whose CD expression has been demonstrated by FACS and Western blot analysis 26 was chosen for subsequent in vitro and in vivo studies. No morphological alterations or differences in cell growth were observed in the AS/CD or AS/neo control clone when compared with the parental AS cell line (data not shown). When we examined the overall 5FU toxicity, all three cell lines (AS, AS/CD, and AS/neo) were equally sensitive to 5FU, with a 50% inhibitory concentration (IC 50 ) of 4 M (Fig 1) . However, only AS/CD cells were efficiently killed upon exposure to the prodrug 5FC (IC 50 of 40 M); thus, these cells were 675-fold more sensitive than the AS/neo or parental AS cells (IC 50 of 27 mM; Fig 1) . As determined by flow cytometry analysis, all three cell lines were shown to express MHC class I and intercellular adhesion molecule 1 (ICAM-1), but lacked expression of MHC class II molecules (data not shown).
Tumorigenicity of the AS/CD cell line in vivo
As a first step of our immunization strategy, two groups of rats were inoculated s.c. with AS/neo (control group) or AS/CD cells. Within 6 days, all animals developed palpable tumors. At day 11, when tumor sizes had reached ϳ3 cm 2 , each group of rats was split in half and treatment of each subgroup with PBS or 5FC was initiated (Fig 2, top panel) . Tumor growth in AS/neo animals continued and was unaffected by 5FC or PBS treatment (Fig 3) . However, all animals that had received AS/CD tumor cells survived (Fig 2, top panel) because after initial tumor growth, complete regression was observed (Fig 3) . Although, the overall outcome (i.e., tumor regression) was the same for both 5FC-and PBS-treated AS/CD tumor-bearing animals, the regression rate was slightly more effective in 5FC-treated rats (day 19) compared with PBS-treated rats (day 25). This difference reached statistical significance starting at day 14 (P Ͻ .05). The administration of 5FC was well tolerated, without any signs of systemic toxicity. Surviving rats remained tumor-free until the next tumor cell inoculation was performed 3 weeks after cessation of 5FC treatment. These results suggest that AS/CD cells have a restricted tumorigenic potential in syngeneic rats, and that complete tumor regression occurs independently of but can be accelerated by prodrug treatment.
Rejection of AS/CD cells and delayed tumor growth of AS tumors
To examine whether this antitumoral reaction depends upon CD expression or also might be directed against unmodified parental AS tumor cells, each of the 16 AS/CD vaccinated and surviving rats was subjected to a second tumor challenge involving inoculation of AS/CD and AS cells. A group of eight previously untreated naive rats received the same tumor cell treatment and served as the control group. All of these control animals developed both AS and AS/CD tumors (Fig 2, middle panel) . Within ϳ13 days, AS/CD tumors stopped growing and started to regress, similar to the animals that had received AS/CD during the first challenge (Fig 2, top panel) . However, complete regression of AS/CD tumors could not be observed in these control animals because they had to be sacrificed due to the size of the rapidly growing AS tumors (Fig 4) . In contrast to these control rats, all animals (16 of 16 rats) that survived the first AS/CD tumor challenge immediately rejected the AS/CD cells after the second tumor challenge (Fig 2, middle panel) , whereas AS tumor cell inoculation caused tumors in all rats. The growth rate of AS tumors in pretreated rats was significantly delayed when compared with the AS tumors in the control animals (P Ͻ .001), and pretreated rats survived up to 3 weeks longer (21-37 days versus 14 days) (Fig 4) . More importantly, in 6 of 16 rats (37%), the AS tumors finally regressed completely and the rats survived (Fig 4) . Tumor regression was complete on day 23 after the second tumor cell challenge.
Immunity against parental AS tumor cells
Because all rats that had survived AS/CD tumor cell challenge in the first part of the experiment apparently were immune against rechallenge with the same cells, but only a fraction (6 of 16) of these animals survived inoculation of tumorigenic doses of parental AS cells, we examined tumor growth in those six rats when rechallenged with AS cells (Fig 2, bottom panel) . All of these pretreated rats rejected inoculated AS cells and remained tumor-free for at least 23 months after this third tumor challenge when the experiment was terminated and the rats were killed. In naive control animals, inoculation of the same dose of AS cells caused rapid tumor growth; animals had to be killed after 13-16 days due to tumor size. These results suggest that systemic immunity against parental AS cells can be induced by genetically modified AS/CD cells.
Cytotoxic T-cell activity directed against AS cells
To investigate whether the antitumoral effect observed in our animal experiment might involve cellular immune responses, chromium release assays were performed for detection of CTLs. AS cells were efficiently lysed (up to 20%) at different E:T ratios by PBLs isolated from rats that had survived AS/CD and AS tumors, whereas PBLs of control rats failed to lyse these target cells (Fig 5) . The same results were observed when AS/CD target cells were used (data not shown). Efficiency of lysis was identical for both AS and AS/CD target cells and was dependent upon prestimulation of PBLs, but there was no difference among the AS or AS/CD cells used for prestimulation (data not shown). We further analyzed whether part of this lytic activity was nonspecific and eventually mediated by NK cells. Using MHC class I-negative YAC cells as targets, a complete lack of or only a low level of lysis (9%) of YAC cells was conferred by PBLs of control animals or pretreated rats, respectively, indicating that the specific cytotoxicity was mediated predominantly by MHC-restricted CTLs rather than by NK cells. Similarly, PBLs of treated rats were unable to lyse the syngeneic sarcoma cell line Sp6S when used as target cells (Fig 5) . These data demonstrate that in rats challenged with AS/CD or AS cells, cytotoxic T cells can be induced that are capable of lysing not only CD-modified but also genetically unmodified parental AS tumor cells.
Lymphocyte infiltration of AS and AS/CD tumors
We also examined the infiltration of CD4 ϩ and CD8 ϩ cells in parental and genetically modified tumors. A representative staining pattern of these tumors is shown in Figure 6 . CD4 ϩ cells, albeit few, were detected in both AS as well as AS/CD tumors independent of 5FC or PBS treatment. Instead, massive infiltration of CD8 ϩ lymphocytes was found only in AS/CD tumors. These in vivo results support the in vitro cytotoxicity data, demonstrating a major role of AS-specific CD8 ϩ lymphocytes in AS and AS/CD tumor regression after vaccination. Moreover, the data also demonstrate the requirement of CD for the activation of AS-specific CTLs.
DISCUSSION
The goal of this study was to examine the immunomodulatory potential of the CD/5FC suicide system on tumor growth using the rat pancreatic AS tumor cell line in syngeneic animals. Our results clearly demonstrate that CD expression is sufficient to increase the immunogenicity of AS cells leading to complete AS/CD tumor regression independent of 5FC treatment in all animals. Concomitantly, 37% of these AS/CD "primed" animals were protected against subsequent challenges with unmodified parental AS cells, and the presence of tumorspecific CTLs in these animals strongly suggests the induction of systemic immunity.
The AS tumor model has been well described and it is known that neither excision of a primary tumor nor vaccination with irradiated AS cells exerts any protective effect, (i.e., the immunogenicity of the AS tumor by itself is too weak to induce a protective immune response). 29 Our observation that CD-modified tumors regressed without prodrug treatment is in contrast to most in vivo studies employing the CD suicide system. In these studies, CD-mediated conversion of 5FC to 5FU was an essential requirement for efficient killing of both genetically modified and unmodified tumor cells and was observed in athymic nude mice as well as in immunocompetent animals. 17,30 -33 One could argue that the discrepancy between our data and those reported by others might be attributable to an unusual high expression level of CD in the AS/CD clone used in the present study. However, the specific CD activity measured for AS/CD cells in vitro was found to be ϳ21 nmol/ minute/mg (K.H., unpublished results). This level of CD expression is similar in magnitude to other CD genemodified tumors that can be eliminated in vivo with 5FC, thus ruling out the unusually high CD expression level as the main reason for the observed immune response in our experimental model system. Alternatively, the mode of 5FC administration or impaired 5FC uptake of these tumor cells might account for the observed difference. This is highly unlikely, because the amount of 5FC used as well as the i.p. application of the prodrug have been demonstrated previously to be the most efficient treatment regimen in animal studies using the CD/5FC suicide gene/prodrug system. 32 Thus, we have to assume that in our system, CD expression significantly increased the immunogenicity of AS cells. Because transfection of AS cells with the neomycin phosphotransferase gene (neo) exerted no effect on tumor growth or tumor rejection, it is obvious that not all foreign antigens have immunomodulatory capacities. Yet the phenomenon is not unique for the CD gene (i.e., other bacterial proteins such as ␤-galactosidase also have been shown to induce immune responses in vivo and in vitro). 34 AS/CD cells were not rejected immediately when inoculated into naive animals. The transient tumor growth will be associated with a longer persistence of the immunogen, which may be required for establishment of a strong antitumoral reaction, eventually leading to complete AS/CD tumor regression in 100% of inoculated animals.
We subsequently asked whether this response is CDspecific or whether by transfection with the CD gene an immune response against the parental AS cells is also induced. In fact, in more than one-third of AS/CD-primed rats that received a challenge of parental AS cells, the AS tumor regressed. Because this antitumoral response was augmented by subsequent tumor cell challenges, CD must have triggered an AS-specific immune response. Protective immunity against genetically unmodified parental tumor cells has been reported in other studies using the thymidine kinase or CD suicide genes, but antitumoral responses in most of these reports were related to prodrug-dependent ablation of suicide gene-modified tumors. 15, 17, 18, 35 The proportion of animals that were protected against further challenge with the parental cells varied in different animal models ranging from 37% (our results), to 48% to 80%, 35 and up to 100%. 17 A massive destruction of CD-modified cells by prodrug treatment was involved in the induction of such protective immunity in one of these studies. 17 In our study, 5FC treatment only exerted a weak therapeutic effect, which was visible as a slightly increased rate of AS/CD versus AS tumor regression. Nonetheless, because four of these six animals belonged to the group of rats receiving 5FC treatment, we cannot rule out a minor contribution of FC treatment to the therapeutic effect. Instead, in the CD systems described so far, protection against parental cells essentially depended upon prodrug conversion. Using immunosuppression studies, Consalvo et al 17 clearly demonstrated that upon CD tumor regression, an immune memory against parental tumor cell challenge was mediated by CD4 ϩ and CD8 ϩ T cells. Although, 5FC failed to cause CD tumor regression in CD8 ϩ -depleted animals, the memory elicited in tumor-bearing mice again depended upon the 5FC-mediated regression of CD-expressing tumors. However, no immune response could be induced by immunization with CD-expressing tumor cells only. Similarly, Mullen et al 35 presented evidence that animals preimmunized with syngeneic, non-malignant, CD-expressing cells rejected unrelated CD-expressing cells in the absence of prodrug treatment. However, no protection against unmodified parental tumor cells was observed. Although these findings differ from our observation that CD in and of itself suffices for the induction of a protective immune response against the parental tumor in 38% of the animals, the aforementioned studies as well as our report clearly point toward an involvement of the immune system in CD-induced tumor regression. Additional evidence is provided by recent reports that demonstrate an increase in the therapeutic efficacy of CD by combined expression with immunomodulatory molecules such as granulocyte-macrophage colony-stimulating factor, 36 interferon-␥, 23 or interleukin-6. 22 Interestingly, prodrug treatment even antagonized the CD-mediated immunogenicity in the absence of such cytokine gene expression, 23 suggesting that before application the antitumoral efficacy of 5FC treatment has to be evaluated for each treatment modality.
We also want to stress the point that by vaccination with CD-modified tumor cells, we clearly induced a long-lasting memory response. While in other studies, follow-up of treated animals was terminated after several weeks, 17, 34, 35, 37 in our experiments no tumors were observed even after 2 years, so that the rats reached normal life span. Because in several other studies tumor recurrence was observed after a period of dorman-cy, 13, 14, 38 this is an important observation that further strengthens the efficacy of the CD-induced, tumorspecific immune response.
With respect to the mechanism underlying this highly efficient antitumoral response, we can clearly state that CD8 ϩ CTLs are dominating the effector phase of the response. This was shown by in vitro cytotoxicity and most convincingly by the massive infiltration of CD8 ϩ cells into the solid tumor mass. The tumor cells themselves express MHC class I molecules at a high level and, in addition, ICAM-1 as a costimulatory/coligation molecule for CD8 ϩ effector cells. Some investigators reported up-regulation of cytokines 39 or MHC class I expression 37 in vitro upon transfection with the herpes simplex virus-thymidine kinase suicide gene as a possible means of facilitating induction and/or the effector phase of the response. This has not been the case in our system, where expression of MHC class I molecules was not modified by transfection (i.e., AS, AS/neo, and AS/CD tumor cells before their inoculation into animals revealed equally high expression levels of MHC class I molecules and ICAM-1). Thus, the observation that only AS/CD tumors but not the parental AS tumor regressed in the naive animal cannot be due to different susceptibilities of AS/CD versus AS for CTL effector cells. The finding that CTLs specific for the parental AS tumor could be induced in vitro when appropriate cytokines were provided strengthens the interpretation. NK cells as yet another cytotoxic effector cell apparently did not play a major role. Lysis of an NK target was low, and the cytotoxic activity was not increased after vaccination with AS/CD tumor cells nor was it augmented during tumor regression. Furthermore, the long-lasting memory observed in our system also argues instead for a T-cellmediated response. Whether a humoral response (e.g., via an Ab-dependent cellular cytotoxicity mechanism) was involved remains to be clarified. Preliminary results indicate the presence of CD-specific Abs only in the sera of rats that rejected AS/CD tumors (K.H., unpublished observations). However, according to the low efficacy of NK cells, a major role of a humoral response in AS tumor regression after AS/CD vaccination does not appear likely.
Having clarified (a) the importance of CD8 ϩ cells in the effector phase of the AS/CD-induced immune response and (b) the essential requirement of AS/CD vaccination for the activation of AS/CD-and AS-specific CTLs, there remains the question of induction of response. Several groups have demonstrated the participation of CD4 ϩ and CD8 ϩ T cells as well as of granulocytes and macrophages during regression of suicide gene-modified tumors and during the reaction against subsequent challenges with parental tumor cells using the thymidine kinase 16, 19, 39 or CD suicide systems. 17, 20 Without question, activation of CD4 ϩ helper T cells is a "conditio sine qua non" for the activation of a memory CTL response. In fact, we observed a minor infiltrate of CD4 ϩ cells in AS as well as in AS/CD tumors. However, an AS-specific response only was observed in the latter case, and previous studies failed to observe activation of CD4 ϩ cells specific for the AS tumor. 40 Therefore, the most likely explanation will be that in our system, expression of the CD gene is essentially required for the activation of the T helper compartment and that a supply of helper factors by CD-specific helper T cells suffices for bystander activation of AS-specific CD8 ϩ CTLs.
In conclusion, our data suggest that nonimmunogenic rat pancreatic AS tumor cells can become highly immunogenic by expression of the CD antigen, thereby inducing a long-lasting antitumoral immune response against genetically modified as well as against unmodified parental tumor cells. Our stepwise immunization strategy successfully protected more than one-third of the animals solely based on the CD-mediated and almost 5FC-independent antitumoral response. The availability of an AS-derived metastasizing cell line 25 will further allow us to investigate whether this approach is also capable of eliminating metastatic disease in our animal model system.
